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• Interleukin-4 (IL-4) is a cytokine that regulates multiple biological functions.
• The recombinant Human IL-4 was cloned and produced under specific promoter in Escherichia coli.
• Through MTT assay, the exposed cells with rhIL-4 were proliferated in a dose dependent manner.
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ABSTRACT
Recombinant DNA technology plays a vital role in improving health conditions by 
developing new pharmaceuticals.  Recently, some of the cytokines as other recombinant 
proteins could be produced using the recombinant DNA technology. The role of 
Recombinant IL-4 in allergy, autoimmunity, and cancer has been investigated.  The 
present study was aimed to clone and produce the Human IL-4 under specific promoter in 
Escherichia coli and assessed its biological functions. The designed hIL-4 gene construct 
was artificially synthesized; subsequently, it was sub cloned into the pcDNA3.1 (+) vector 
in HindIII restriction enzyme site. Recombinant plasmid was transferred and expressed 
in BL21 cells. The rhIL-4 protein was evaluated by SDS-PAGE and Western blotting. 
It was purified by Ni-NTA affinity chromatography. The purified protein concentration 
and also accuracy were determined by ELISA. MTT assay was applied to evaluate the 
biological activity of rhIL-4 on the erythroleukemic cell line proliferation.  The rhIL-4 
gene was successfully cloned and transformed into expression E. coli cells. As a result, 
a specific band was observed both on the SDS-PAGE and nitrocellulose membrane after 
Western blotting. The purified protein concentration was equal to 500 pg/ml. The MTT 
assay indicated that the exposed cells with rhIL-4 were proliferated in a dose dependent 
manner. The rhIL-4 gene under specific eukaryotic promoter was successfully cloned 
in the prokaryotic system and the transcription was carried out by T7 RNA polymerase. 
Therefore, mass production of IL-4 could be a great help in clinical trials and research 
studies. Additionally, prokaryotic system used in current work was less costly and less 
time-consuming.
 Production Design of Efficient Recombinant Human Interleukin-4 
(rhIL-4) under Specific Promoter in Escherichia coli
Original Research Article
Trends in Peptide and Protein Sciences
Volume 3 (2018): e4
Article history:
Received: 3 July 2018
Accepted: 15 August 2018
DOI: https://doi.org/10.22037/tpps.v3i0.21996
M. Vahidi et al. / TPPS, Volume 3 (2018): e4
2
Introduction 
Cytokines are a large and heterogeneous group of 
secreted proteins that are produced by different types of 
cells (Werwie et al., 2017). About 180 genes in the human 
genome encode the proteins with structural property of 
the cytokines (Zhu and Stephens, 2017). Each cytokine 
is able to act on a variety of cells with several different 
biological effects (Abbas et al., 2014).
Interleukin-4 (IL-4) is a cytokine that regulates 
multiple biological functions; including proliferation, 
differentiation, and apoptosis in several cell types of 
haematopoietic and non-haematopoietic origin (Paul, 
1991; Nelms et al., 1999). This cytokine is a growth 
and survival factor for lymphocytes. Although it was 
discovered as a B cell differentiation and stimulatory 
factor, its role in regulating T cell differentiation is 
critical during the immune response (Vitetta et al., 
1985; Mosmann and Coffman, 1989; Seder et al., 1992; 
Zubiaga et al., 1992; Illera et al., 1993). This cytokine 
is a monomeric, approximately 13-18 kDa, Th2 cytokine 
that shows pleiotropic effects during immune responses. 
Human IL-4 is a polypeptide chain containing 153 amino 
acids (P05112 IL4_HUMAN). It has a molecular mass of 
17,492 Da as follows (Chomarat and Banchereau, 1998; 
Benczik and Gaffen, 2004).
It is a glycosylated polypeptide that contains three 
intrachain disulfide bridges and adopts a bundled four 
alpha -helix structure (Redfield et al., 1991). IL-4 exerts 
its effects through two receptor complexes (Nelms et al., 
1999; Muller et al., 2002). The type I receptor, which is 
expressed on hematopoietic cells, is a heterodimer of the 
ligand binding IL-4 R alpha and the common gamma 
chain. The type II receptor on non-hematopoietic cells 
consists of IL-4 R alpha and IL-13 R alpha 1. The type 
II receptor also transduces IL-13 mediated signals. IL-4 
is primarily expressed by Th2-biased CD4+ T cells, 
mast cells, basophils, and eosinophils (Chomarat and 
Banchereau, 1998; Benczik and Gaffen, 2004). It promotes 
cell proliferation, survival, and immunoglobulin class 
switch to IgG4 and IgE in human B cells, acquisition 
of the Th2 phenotype by naïve CD4+ T cells, priming 
and chemotaxis of mast cells, eosinophils, and basophils, 
and the proliferation and activation of epithelial cells 
(Paludan, 1998; Grone, 2002; Corthay, 2006; Morales et 
al., 2010).
IL-4 plays a dominant role in the development of 
allergic inflammation and asthma (Rosenberg et al., 
2007; Morales et al., 2010). In contrast with allergic 
diseases, IL-4 acts as an anti-inflammatory cytokine and 
could be considered as a potential tool for the treatment 
of autoimmune diseases (Feldmann et al., 1996). The role 
of IL-4 in cancer has also been investigated (Margolin et 
al., 1994; Benedetti et al., 2000; Shintani et al., 2017).
Regarding the wide range of cytokines’ biological 
activities the production of recombinant form of these 
proteins is crucial for both the development of new 
protein drugs and the structural determination of drug 
targets. As such, recombinant protein production has 
a major role in drug development. Bacterial hosts are 
commonly used for the production of recombinant 
proteins, accounting for approximately 30% of current 
biopharmaceuticals on the market. The results of many 
previous studies indicated that genes of eukaryotic 
protein could be cloned in E. coli expression vectors as a 
transgenic prokaryote microorganism. E. coli is a suitable 
host for expressing stably folded, globular proteins from 
prokaryotes and eukaryotes. Also, the doubling time of E. 
coli is about 20 min and the high cell density cultures are 
easily achieved. Transgenic bacteria can be used for the 
production of valuable eukaryotic proteins that are hardly 
acquired (Bettelheim et al., 1991).
The present study was conducted to produce IL-4 
cytokine by recombinant DNA technology methods 
under eukaryotic specific promoter in Escherichia coli, 
an efficient and low cost host, according to the necessity 
of self-sufficiency in our country and in order to benefit 
from them in clinical trials and research studies. 
Materials and Methods
Preparation of recombinant hIL-4 gene construct
For design of recombinant hIL-4 gene construct 
has been used as a specific human promoter of the 
gene  that was achieved from Uniprot data bank 
(ctcggtttcagcaattttaaatctatatatagagatatctttgtcagca 
TTGCATCGTTA). Also, the sequence of hIL-4 with 
signal peptide fragment was obtained from UniProtKB 
Databank with Entry no. P05112 and synthesized into 
pGH plasmid (GeneRay, China). 
The IL-4 sequence fragment was sub-cloned into the 
expression vector to produce recombinant expression 
plasmid. So, the pGH plasmid was digested with HindIII 
(Fermentas, Lithuania). The  desired fragment was 
extracted and purified using a DNA gel extraction kit 
(Qiagene, USA), then, it was cloned into the digested 
pcDNA3.1(+) vector (Invitrogen, USA) using T4 DNA 
Ligase (Fermentas, Lithuania).
Recombinant plasmids were confirmed with PCR by 
universal primers (Table 1). Amplification was carried 
out in 30 cycles of 30 sec at 94 °C, 40 sec at 50 °C, and 40 
sec at 72 °C. The recombinant plasmids was also digested 
by NheI (Fermentas, Lithuania) and lastly, proved by 
nucleic acid sequencing.
Prediction of transcription factor binding sites by 
PROMO server
PROMO is a virtual laboratory for the identification 
of putative transcription factor binding sites 
3
Efficient production design of rhIL-4 in E. coli
(TFBS) in DNA sequences from a species. 
PROMO is using version 8.3 of TRANSFAC. 
 TRANSFAC database was used to construct specific 
binding site weight matrices for TFBS prediction 
(Messeguer, Escudero et al. 2002).
Expression of recombinant hIL-4 gene
The E. coli strain BL21 was transformed with the 
recombinant hIL-4 vector for expression of the protein 
and was cultivated in Luria Bertani agar supplemented 
by 100 µg/ml of ampicillin. The transformed colony was 
inoculated in 3 mL  LB broth medium containing 100 
µg/ml  of ampicillin and incubated at 37ºC in shaker 
incubator at 200 rpm, overnight. After 16 hours, the 
cultured bacteria were inoculated in a 50 mL flask and 
incubated for 3 hours at 37ºC in shaker incubator at 200 
rpm. 
     The culture in the logarithmic phase (at OD600 = 0.6) 
was centrifuged at 4000rpm for 15 min and the sediment 
was resuspended in a lysis buffer (50 mM Tris base, 
10% glycerol, 0.1%Triton X-100) (Merck, Germany). 
Subsequently, the suspensions of bacterial cells were 
lysed by sonication on ice. Then, the two volumes of 
acetone (Merck, Germany) were added and kept at  -20 
ºC, overnight and finally, centrifuged at 4000 rpm for 
15 min. The pellet was analyzed by 15% SDS PAGE 
electrophoresis stained with Coomassie brilliant blue 
and the quantity of the expressed protein was visually 
estimated by comparing the intensity of the protein 
bands.
Recombinant hIL-4 protein analysis by western blotting
Recombinant proteins were electrophoretically 
transferred to a nitrocellulose membrane (Wathman, UK). 
TBS buffer including Tris-Buffered Saline supplemented 
by 3% Bovine Serum Albumin (Sigma, USA) was used 
for blocking the membrane. The membrane immersed in 
1:2000 dilution of ALP (alkaline phosphatase) conjugated 
anti S-tag monoclonal antibody (Abcam, UK) for 2 hours 
at room temperature. Subsequently, it was visualized for 
color after development in NBT/ BCIP substrate solution 
(Roche, Germany).
Purification and identification of recombinant protein
The rhIL-4 fused to S-tag peptide was purified from 
cell lysate by using protein S resin (Novagen, USA)  as 
specified by the manufacturer’s instructions. The purified 
protein was concentrated and desalted using Amicon 
Ultra-15 units with cut-off 10 kDa (Millipore, Germany). 
Human IL-4 Quantikine ELISA Kit (R&D systems, 
USA) was used to measure the concentrations of purified 
recombinant hIL-4. 
Cell culture and efficiency evaluation of rhIL-4 by MTT 
assay
Erythroleukemic cell line (TF1, ATCC2031) was prepared 
from National Cell Bank of Iran (Pasteur Institute, Iran). 
This cell line was sub-cultured in RPMI 1640 (Gibco, 
Germany) media supplemented with 10% fetal bovine 
Table 1. Universal Primers sequences.
Name Sequence (5 to 3)
pcDNA3.1(+) F TAATACGACTCACTAATG
pcDNA3.1(+) R TAGAAGGCACAGTCGAG
Table 2. Statistical analysis of hIL-4 Proliferation.
Concentration (ng/ml) OD Mean SD P-value
0.001 0.035 0.035 0.032 0.034 0.002 0.009
0.003 0.041 0.041 0.045 0.042 0.002 0.006
0.01 0.1 0.1 0.097 0.099 0.002 0.025
0.03 0.139 0.13 0.145 0.138 0.008 0.011
0.1 0.18 0.176 0.181 0.179 0.003 0.003
0.3 0.21 0.22 0.249 0.226 0.020 0.005
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serum (FBS), 100 units/ml penicillin (Gibco, Germany) 
and maintained at 37°C in a humidified atmosphere with 
5% CO2. 
MTT (3-(4,(5-dimethylthiasol2-yl)-2,4,diphenylte
trazoliumbromide)) as a Colorimetric assay was used 
to evaluate the biological activity of rhIL-4 on the cell 
proliferation. The cell suspension was prepared and then 
2×104 cells were seeded in each well at 96-well cell culture 
plate. After 24 h of incubation, the purified recombinant 
hIL-4 at the concentrations of 0.001, 0.003, 0.01, 0.03, 
0.1, and 0.3 ng/ml were added to related groups.  
The 96-well cell culture plate was incubated at 37 ºC 
with a humidified atmosphere of 95% air and 5% CO2 
for 48 h. Then, 10 µl of MTT solution (0.5mg/ml in PBS) 
(Sigma, USA) was added per well and incubated for 4 h 
to form formazan crystals. Subsequently, the supernatants 
were slowly removed and 100µl of DMSO (Sigma, USA) 
was added to each well to dissolve the formazan crystals 
in the cells. The absorbance was measured at 570 nm with 
the reference filter of 620. The amount of color produced 
is directly proportional to the number of viable cells. All 
assays were performed in triplicates. 
Statistical analysis
All experiments were performed at least three times. 
Descriptive statistics (means and standard deviations) 
were calculated using SPSS Software. P value of < 0.05 
is considered to be statistically significant.
Results and Discussion 
The growth in the use of recombinant proteins has greatly 
increased in the recent years. Bacterial systems remain 
most attractive due to low cost, high productivity, and 
rapid use (Terpe 2006). In present study, we report the 
cloning of human IL-4 cytokine in E. coli as a prokaryote 
host  and the gene expression was evaluated by the 
specific promoter of the same gene under the control 
of the T7 RNA polymerase and we would eliminate 
the need for chemical inducers particularly in large-
scale cultivation of recombinant bacteria. According to 
PROMO server analysis results of specific promoter, 
we found several binding sites for GR-beta, TFIID, 
HNF-3alpha, C-EBPbeta, XBP-1, and GR-1 that were 
recognized by E. coli DNA polymerase.   Eukaryotic 
Promoters are much more complex and diverse than 
prokaryotic promoters. T7 RNA polymerase requires the 
associated protein sigma factor to bind the core promoter 
region stably and the transcription of the template strand 
can initiate. The specific IL-4 promoter is controlled by 
various DNA regulatory sequences including enhancers, 
boundary elements, insulators, and silencers. In fact, how 
T7 RNA polymerase locates this specific binding site in 
the large excess of non-promoter DNA remains a field of 
intense investigation. However, the rational choice of the 
adequate promoter system and host for a specific protein 
of interest remains difficult (Kanhere and Bansal 2005). 
Escherichia coli is one of the organisms of choice for 
the production of recombinant proteins. Its use as a cell 
factory is well-established and it has become the most 
popular expression platform (Rosano and Ceccarelli 
2014). Large-scale protein expression trials have shown 
that <50% of bacterial proteins and <15% of non-
bacterial proteins can be expressed in E. coli in a soluble 
form, which demonstrates the versatility of the system 
(Braun and LaBaer 2003).
The detection and purification of proteins can be 
problematic. These processes can be generalized by using 
recombinant DNA technology to produce fusion proteins 
in which target proteins are fused to carrier polypeptides. 














Figure 1. The designed codon optimized human IL-4 sequence under gene promoter. Highlight sequence indicated IL-4 specific promoter, black 




















CTCGGT AG AAT T AAA TATATATAGA ATATCTTTGTCAGCATTG ATCGTT TG GTC CA CT CC ACT
CTTCCCCCTCT TTC TCCTGCTAGC TG GCCGGC ACTTTG CCACGGACACAAG GCGATATCACCTTACAGGAGATC
ATCAAAACT GAA AG CTCA AGAGCAGA AC C TGCA CGAG A GTAACAGAC TCTTTGCTG CT CA G
AACACAACTGAG GGAAACCTTCTG AGGGCTGCG CTGTG C GCAGTTCTACA C ACC TG AGGACACT GC
TGCCTGGGTG GACTGCACAGCA TTC ACAGGCACAA A TGA CC A T CTG AACGGCTC A GG ACCTCT
GGCCTGGCG G T AATTCCTGT CTGTG AGGAAG CAA CAG T CG TGGAAA C T TGG AA GCTA AGACG







CTCGGTTTCAGCAATTT AA C T TAG GA A C TT TCAGCAT GCA CG TAA GGGT TCA TC CAACTG
TT C CC CTG T CT T CATGT CGG A TCC GG CACAA TG GATAT AC T ACAGGAGATC
CAAAA TT A AGC TC GC GA C TG C ACCG A GACA TG G TC AAG
A A CTGA G AA TCT CAG G T G CT C C GTT TA G CACCATGA GA TCGC
CC G T ACA TT CA A A T C T TGA ACG CT AC AAC TCT G
C T G CT T T T GA G A CAGA C T GA A T T A CT AAGA G
AT A G G AAT TCA TT G TG  
C
TG C G C C AG
G
C C G








C C G TCAGC T ATCTATATATAGAGA ATC TGTCA T CATCG T AT GT A CT C ACTG
T C G C T CTGC AGC G C GC AC TGT AC G CAC AG GCG A T C GAGATC
T AC T ACAG C A GC GAAGAC GT CACC G TG CA ACAT TGCTG CT C AG
AC ACT AG GG ACC TCT A CTGCGA GT CT CGG AG TCTACAG CA C T AGA GACACTCGC
T CTG GTGCG T CAG AG T CACAGGCAC AGC G T GA TCCT A A G TC CAGG ACCTCT G
CT GC GC GAA CCT TG A G G C C GAG ACG T GA AC TCTT AA GGCT AGACG







TCAGC C G A G CAGCA TGC TC T A G T A T C ACTG
C G C CTGCT A G GC G T G A C T CA GATC
TC C TG G T C C G C GTG AG G C C CA TG TG T C AG
AC C CT G A G A CTGCA G C ACTGT T C GC G T AG C T G A GA A T GC
T CT GACTG CAG G T C A CAG T A GA T T AC GCTCG A G A CT G
G CT GC GC TG A T GT C TG A G AG C A C AGTACG T G AC C T G CT GACG







TC G T GC T A C T G A C G GCA TG C AT G T ACTG
C G GC G A T A T AC C A G T C T C GATC
G C GA C A TG GT A C TG C AG
C G T CA T A G C G G A T GC
TG T G TG CA T C G A C G T T G G G A CT G
C C G C C AG A G G ACG













CTCGGT G AA AA T G A TT TC GCA G T
TT G T CT T A G G C C T G CC GG C A T T A A C
TCAA A TTTG A GC C GCAG A A TG C GAG A T G G CT C AG
A CACA A T TGTG AG C T GGA T
CC G TG A T AGC GT C A G A C CT T TC GA TC AC G CCT G
G C G C A C TG CC GA AC TT GAAAAC TCTT AAA G T A GA G







CTCG T CAG A A TATATAGA C GTCA T T T C
CT C T GT CT GCT GCA G G CA CT T A A A GTGC TATC C G AGATC
ATCA T GA CA A AG A G T T T AC G GT C G A G
A CAC TG G G A C T G T C A TGT C C CAGT T CAGC A A G A AC GC
TGC TG TGC G C T A AG CA CAGCT T G T A C CT G AG C TCTG
G C T G T A TG A GC C GTAC T A C T G C







CTCGGTTTCAGCAATTTTAAATCTATATATAGAGATA TTTG CA G A GT A C G
CTTCCCCCTCTGTTCTTCCTGCTAGCATGTG GG AA C CGGACA GC ATATC CA G G
ATCAAAACTTTGAACAGCCTCACAGAGCAGA GA TC G GC G G C T C C A
AACACAACTGAGAAGGAAACCTTCTGCAGGGCTG G CTG T C C T C CAG A G C
TGCCTGGGTGCGACTGCACAGCAGTTCCACAG A AA TG TT C G G C G A T
GGCCTGGCGGGCTTGAATTCCTGTCCTGTGAA AA C AAC A A T C T A AC TCT G A T A







CTC GTTTCAGCAATTTT TCT T G T T A TTA T A AA
CTTCCC CTGTTCTTC T G
A CA A CTTTGAA GCC A G TG C
AAC CAA AGAA GA C T CT G G AA CT G
TGCC GGGTGCGAC GC C G TCC G C C GC C A CC ACGGCT G AG ACCTC G








CGGTTTCAGCAATTTT T T T G G TT T GT C C AA
T C C C T TT A T T A T C
T A T CA CCT A A C C AC G TT C C G
CAAC A AG A T C CT G CC TAC GC C AT G G TC C
T GT CGACTGCACAGCAGTTCCA G C CA C G T TCCGA CCT AC GC C C AACCTCTG








C G T A C A T T G T T TCT AC G
C T C G TC T CTG
TC AC TG AC G T C GCT T G
A AC CT A A C C G C C G AC C ATGAG A A A C C
TG CT T GACTGCA AGCAG CAC C C AGC GC GA A TG AC GCTCG CA G CTCT G
G CT C C TG A T CT C GTG A AG C A CAGAGTACG T G AC TC T G A GCT AGACG







CT TT AGC ATT AA C G A
CTT T G C GC T CA G C T TA C A T
A C CTT A CT A G A CT A G C T T G
A C T G A C T C G A C TG C T
TGCCTGG T C A G G T A GCA T C G TTCC CGG T GA GG A CT G
GGCCTGGC CTTG TCC G CC AA A CCAA C G T CGTT GAA CTT GGAA GGCTAA G C







CG TT A T AA C G T G T G
C T C TG T C G AT T T A A AGA
ATCA A C T G AG A A G G
A C C C G G CTT TG G T C C A T A G CT
TGCC A AC C G T CAGG G T T GA AA G CT A A A TCTGG
GGCCT TT A CC G TG AAG C G GTA T AAACTTCT GGAAA CT G







CTCGGTTTCAGCAATTTTAAAT TATATAT G G G T A T
CTTCCCCCTCTGTTCTTCCTGCT GC TGTG CG T TCC T
ATCAAAACTTTGAACAGCCTCACAGAGCAGAA A A T CTTT T C
AACACAACTGAGAAGGAAACCTTCTGCA GGCT G C G C CC T G G TC









CTC T C GCAATTT A T T C
T C CCTC T T TG C G A C A
ATCA A CTT A CA T ACA A T T T T
ACAACTG AA AA T CA G TT T C C G C C
TGCCTG G G GAC GC T CC G GC TC TTCCTGAAA G CTCGACAGGAACCTCTGG
GG G GG CTTGAATTC TGT T T A G AA CC C AGAG ACGTT AA CTT TTGGAAAGGCTAAAGACG







CTC GTT C C A T T T T T G CTC CAA G
T TCT T T T T A
A AC T C C A T A C A
A AC ACT A A T C G GT C T T G C G AC C
TG T GTGCG C GC C C C T CTG AC CTCGACA G A CTCT G
G CT G GC T T TGT CTGTG A G A C CAGAGTACG T G C TC T G A GCT AGACG







TC G TT A C A TT T T GT G CA ACTG
C C A C
ATC C TG A G CT
A T A A C C T A G
T CT T G CT CA C G C T T C T CTG AC G TCG CA G A CT G
G C C C T T C GT C G A G AG C A C A T CG T G AC C T G A GCT GACG







C A T AT G T C T T TG T C C T AA TG
TT T C TG C A GGA C C A TA GGA ATC
T G G T G T G T C T C A
A G T C CT CC G ACACTCGC
C C G ATTCCTGAAAC CTC A AGG AC TCTGG








CT G T A A AA G G A G
CTT C G G C G A T C A A T T A GG T
A C A G G A TT CC A A G
T T T C TT TG G
G T G GG








CT GGTTTCAGCAATTTT AA AGA A T TA T A C G
CTT CCCCTCTGT C G G T T TT G A
A AA T C C G T C A G C
A A GA AA A T G C A A
G C T C
TT T TT G A G G







TCGGT CAGCAATTT AATCT A TG G A T T A
CT CCC C TG TCTT C AG A G G G T
A CA A TTTGA C G G CT T T T
AACAC A T G AG C G
GG G G A C A
C GG T T G







CTCGGTTTCAGCAATT A ATC ATA AT G TCTTTG C T T
T C C T T C T G G T T A T
AAAA TT A T A
G C G G AG A AT AG T









CT AGC AT GAG C TG C A
C GT C T A G TC C G G T A C T C A A C
TC C TG A C G CT C G T C A T G
A A G C TT AC A A A T
T G C G T T A GA
G T A G A C T C
 
A G












C G T T A ACG








C A C A
G
T G A C
G CT G CG







TT GCAATT T T T G C
C
G A CG
GT TC G TC
T G C T TCTT T AAGACG












G T CA CG T AA TTCTTGGAAA CTAAAGACG











T CT A T
C T G CT T GG AA GCT A GACG







TTT GCAATTTT CG C ACTG
T A A T
AC A T C G
C C G T AA CCTCTGG
T C GA C T G CC A TTG AAAC TCTT A G CT AAGACG







CTCGGTTT AGCAATT T A T AT TT A C A A CT
C T C
A CAAA T
A C TG G A
T CCTGGG G T C
G C A T G







C CGGTTTCAGCAATT A A A AT T TC C C C
TTC CCC GT
T AAAACTTT G C G T
AC ACT AG C A
T CCTG GT CG CA TT G
CT GCG G A T G AC







CTCGGTTTCAGCAATTTT A T G G C A AT T
CTTCCCC T T CTTCCT C A A
ATCAAAA T G AGC T T
AA A AA G GG AA G
TGCCTGGG G TG GC
GG CTGGC GCTT T A T







CTCG T CAGCA T A TCT T T G G A T AA TC C A
CT C TCT T C T A G
A T G A G
A A A CTGAG A
GC G G T
G C T C T







CT G T CAGCA T T G CA G A
CT C T G C CTA A
A A CT GA
A GA G A
TG G C G G
G TG T C







CTCGG A CA TTTT C G T T A A G
CTTC TG C A A
ATCA TTTG CA A
AA A TG G G
GCC C A
GGC T




















G TT AAT G A A
T
A G








C GTT T C T
G A
A T T








C CGGTTT AG A TC A AG G TT C A A
TT C GT G G AA










CT GGT GCAAT T G A T
TT T G C G A G G











CT GGT CA CAA A C G G CA T A G A
CTTCC G G A A G A A G
ATCAA T G G C













































CT G T G A TC
T T G G CT
TC CT G A
G
TGC G T A G








CTCG T A CA T A CA C A C
CT C TG C G A











CTCGG T AGCA T T T A GG C C AA G
CTTC C T G A A
ATCA A T G C C
AACA TG G C
TGCC G
GGCCT







GT A CAATTTT AT C AA A
T
G
CC G A G







T A CA T AT AT T C A G
T
T











C CC C A C G A C A G C







GT A CAATTTT A A T A C C G
A TT A







CAA T T G TG
T
T A A G C







T A CA TT T












T C TG T G






































G C G T














































CTC T A C A CT G GT T
C G A
ATC C G
C C TG G
TG
T







CT G T A A TC T G
CT G A T G
ATC T G
A C TG
TGC TG T C
G C T T







CT GGTT CA A A C G T C G
CTTC G A A A C









C G G T A AG GA T TG C T A
G G


















C C G A AT G T G A T G
AG TC











T G G G CA T G










T TT T T AA TG
T T ATC
T C T AAG
C T GAAGG A T GC
C C G TCG C G AC CTGG








TT C G T AACTG
T A GATC
T T A G TCCAAG
T A A T GC
C CG TC C GGAAC CTGG












G T A C T T G























TCG T CA T T A T TG C C C
T T
A A
A A A A
C T
G C TG CG T T C C T CT
ATCATG GAGA T T C T C C G  
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the facile detection and purification of a fusion protein. 
S. Tag has several additional properties that are desirable 
in a carrier. The S .Tag carrier combines a small size (15 
amino acid residues) with a high sensitivity of detection. 
S. Tag is composed of four cationic, three anionic, 
three uncharged polar, and five nonpolar residues. This 
composition makes S. Tag an excessively soluble peptide 
with little structure and net charge near neutral pH. The 
S. Tag carrier is therefore unlikely to interfere with 
the proper folding or function of a fused target protein 
(Raines, McCormick et al. 2000). Accordingly, S tag was 
considered as fusion part for recombinant production and 
facile purification of recombinant IL-4, without need of 









Figure 2. The Plasmids digestion by Hind III restriction enzyme. (A)  lane1, intact pcDNA3.1 (+), lane2, pcDNA3.1 (+) digested by Hind III.  (B), 









Figure 3. (A) Confirmation of pcDNA3.1 (+)/hIL-4 cloning with PCR by plasmid universal primers; Lane1, universal PCR product of pcDNA3.1(+) 
as negative control. lane2; 988 bp PCR product of the cloned fragment; Lane M, DNA size marker 100-1000 bp (Fermentas, Lithuania). (B): 
Confirmation of pcDNA3.1(+)/hIL-4 cloning with digestion by NheI restriction enzyme; Lane1, 698 bp fragment of recombinant plasmid. Lane 
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Recombinant protein production has a major role in 
drug development accounting for approximately 30% of 
current biopharmaceuticals on the market (Overton 2014).
Recombinant hIL-4 gene construct and promoter analysis
Here, we showed the designed codon optimized sequence 
(JCAT server) under gene promoter (highlighted in Fig.1). 
According to PROMO server analysis results of specific 
promoter, several binding sites for GR-beta, TFIID, HNF-
3alpha,C-EBPbeta, XBP-1, and GR-1 were recognized by 
E. coli RNA polymerase. 
Recombinant hIL-4 gene cloning into pcDNA3.1(+) vector
pcDNA3.1 (+) vector  and pGH plasmid were digested 
with HindIII restriction enzyme (Fig.2). The pcDNA3.1 
(+)-rhIL-4 plasmid was confirmed by universal PCR 
and restriction analysis. Fig. 3 (A) shows PCR product 
of recombinant pcDNA3.1 (+)-hIL-4 plasmid (988 bp 
fragment) and recombinant plasmid digested by NheI 
restriction enzyme. Fig. 3 (B) shows 698 bp fragment of 
recombinant pcDNA3.1(+)-hIL-4 plasmid. Sequencing 
results confirmed the presence of hIL-4 gene in 
recombinant construct in an accuracy position.
SDS-PAGE and western blot analysis
The expression of recombinant hIL-4 protein was 
detected and compared with control forms of the bacteria 
by SDS-PAGE analysis and showed a specific protein 
band. Recombinant protein expression was confirmed by 
western blotting (Fig. 4). 
Purification of recombinant hIL-4 protein
Purification of the recombinant protein was carried out 
using S protein resin (Fig. 5). The purified protein was 
concentrated and its concentration was determined by 
Human IL-4 Quantikine ELISA Kit (R&D systems, USA) 
against the rhIL-4 specific antibody equal to 500 pg / ml.
Recombinant hIL-4 proliferative activity assay
TF1 cell line was incubated in serum free RPMI 1640 
with rhIL-4 for 48 hours. MTT assay demonstrated that 
the exposed cells with rhIL-4 were proliferated in a dose 
dependent manner in comparison to the control group 
(Fig. 6).
Most biotechnology pharmaceuticals are recombinant 
in nature which plays a key role against human lethal 
diseases. Recent advances in the cloning of cytokine genes 
and the availability of recombinant material have led 
investigators to conduct clinical trials with these agents 
(Khan, Ullah et al. 2016). For instance, Wong, Lotze et al. 
(1992) demonstrated that Administration of recombinant 
IL-4 to humans regulates gene expression, phenotype, and 
function in circulating monocytes. Monocytes taken from 
patients before therapy and cultured with and without LPS 
exhibited normal patterns of monokine-specific (IL-1 beta 
and TNF-alpha) mRNA expression, as well as secretion of 
peptide. The addition of rIL-4 to these cultures; however, 
resulted in the down-regulation of both gene expression 
and peptide release. Furthermore, monocytes from post-
therapy patients exhibited reduced production of PGE2 
and superoxide anion, compared with cells obtained before 
therapy. This effect persisted in culture independent of the 
Figure 4.Western blot analysis of the recombinant protein 
expression.  Lane 1, recombinant hIL-4 protein, Lane 2, BL 21 cell 























Figure 5. SDS-PAGE Analysis of the purified recombinant protein 
after purification. Lane 1, bacterial lysate negative control; Lane 2, 
bacterial lysate after 3h incubation; Lane 3, purified protein.
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further addition of exogenous IL-4.
In other study Shintani, Ito et al. (2017) demonstrated 
that IL-4 administration at an acute phase of Myocardial 
Infarction enhanced cardiac repair through enhancing the 
M2-like macrophage-involved self-repair mechanism that 
represents IL-4 has great potential as a new (re-purposed) 
biological drug for the treatment of acute MI, encouraging 
the further development toward early clinical application.
As a multifunctional cytokine that can augment 
certain T cell responses, IL-4 is being evaluated as a 
possible therapeutic agent in the treatment of cancer 
patients. Benedetti, Pirola et al. (2000) demonstrated that 
retrovirus-mediated transfer of the gene for interleukin-4 
was an effective treatment for rat brain glioblastomas. 
They transferred the gene for interleukin-4 into C57BL6J 
mouse primary neural progenitor cells and injected those 
cells into established syngeneic brain glioblastomas. This 
led to the survival of most tumor-bearing mice.
In phase II studies of recombinant human interleukin-4 
in advanced renal cancer and malignant melanoma by 
Margolin, Aronson et al. (1994), rIL-4 was administered 
intravenously. They concluded that IL-4, when given as 
a single agent on this schedule at maximum tolerated 
dose, does not possess meaningful activity in renal 
cancer or melanoma. In similar study, Whitehead, Lew 
et al. (2002) have also used the recombinant human 
IL-4 by subcutaneous injection. The results of this study 
showed IL-4 in this dose and schedule is not useful for 
the treatment of patients with disseminated renal cell 
carcinoma. These findings clearly indicate that the effect 
of IL-4 in cancer is more complex. 
Production of dendritic cells is another application of 
the IL-4. Romani, Reider et al. (1996) used the recombinant 
IL-4 cytokine to produce dendritic cells from human 
peripheral blood monocytes. Bender, Sapp et al. (1996) 
also used the peripheral blood monocytes in the presence 
of recombinant IL-4 cytokine for the production of 
dendritic cells.  Dauer, Obermaier et al. (2003) introduced 
a rapid production of dendritic cells from peripheral blood 
monocytes in the presence of recombinant IL-4 cytokine.
The molecular mechanisms involved in IL-4 
signaling, and especially in the activation of STAT6, may 
be investigated as potential targets for the development of 
novel treatments (Zamorano, Rivas et al. 2003).
Conclusion
Cloning and expression of the IL-4 proteins for a variety 
of applications were exercised by several researchers up to 
now (Struhl, Cameron et al. 1976; van Kimmenade, Bond 
et al. 1988). In current study IL-4 gene was successfully 
cloned in prokaryotic system and then biological activity 
of rhIL-4 measured through a cell proliferation MTT assay 
using TF-1 human erythroleukemic cells. Today, wide 
range of cytokine assays are available. As biologically 
active entities, cytokines cannot be fully characterized by 
physicochemical methods alone. Thus, biological assays 
have become increasingly important for their biological 
characterization and potency determinations. These 
bioassays include measurement of stimulation or inhibition 
of cell proliferation or cytotoxicity by MTT (Sachdeva 
and Asthana 2007). Kitamura, Tange et al. (1989) have 
found that it is possible to use TF-1 in bioassay systems 









Figure 6. Recombinant Human IL-4 stimulates the TF-1 human erythroleukemic cell line Proliferation.
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cytokines stimulate the proliferation of TF-1 cells and IL-4 
and IL-6 extend the survival of TF-1 cells. The results of 
the present study similarly demonstrated that rhIL-4-S tag 
could stimulate the TF-1 human erythroleukemic cell line 
proliferation in a dose dependent manner. 
Considering that rhIL-4 is not produced in our 
country and should be made from other countries at a 
high cost. Therefore, mass production of IL-4 can be a 
great help in clinical trials and research studies. On the 
other hand, in this study, the production of IL-4 was made 
in the prokaryotic system, which is less costly and less 
time-consuming than the eukaryotic system. Also, using 
prokaryotic system, we could produce more of IL-4 than 
eukaryotic ones, which are very important in large scale 
protein production.
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